Table 3.

Responses for patients with measurable disease by arms.

	Cohort 1	Arm A	Exp A	Arm B	Exp B	Arm C	Exp C
	CDS	CDS	CDS	R-SDS	R-SDS	A-SDS	A-SDS
Response criteria, n (%)	(n = 3)	(n = 10)	(n = 4)	(n = 10)	(n = 3)	(n = 10)	(n = 4)	All patients (N = 44)
Confirmed ORR per RECIST 1.1 (95% CI)	1 (33.3) (0.8–90.6)	0 (0.0–30.9)	0 (0.0–60.2)	1 (10.0) (0.3–44.5)	1 (33.3) (0.8–90.6)	0 (0.0–30.9)	0 (0.0–60.2)	3 (6.8) (1.4–18.7)
PR (95% CI)	1 (33.3) (0.8–90.6)	0 (0.0–30.9)	0 (0.0–60.2)	1 (10.0) (0.3–44.5)	1 (33.3) (0.8–90.6)	0 (0.0–30.9)	0 (0.0–60.2)	3 (6.8) (1.4–18.7)
SD (95% CI)	0 (0.0–70.8)	3 (30.0) (6.7–65.3)	0 (0.0–60.2)	4 (40.0) (12.2–73.8)	0 (0.0–70.8)	5 (50.0) (18.7–81.3)	2 (50.0) (6.8–93.2)	14 (31.8) (18.6–47.6)
PD (95% CI)	2 (66.7) (9.4–99.2)	7 (70.0) (34.8–93.3)	4 (100.0) (39.8–100.0)	4 (40.0) (12.2–73.8)	2 (66.7) (9.4–99.2)	5 (50.0) (18.7–81.3)	1 (25.0) (0.6–80.6)	25 (56.8) (41.0–71.7)
Missing or unevaluable	0	0	0	1 (10.0)	0	0	1 (25.0)	2 (4.5)
ORR per mRECIST (95% CI)	1 (33.3) (0.8–90.6)	0 (0.0–30.9)	0 (0.0–60.2)	1 (10.0) (0.3–44.5)	1 (33.3) (0.8–90.6)	0 (0.0–30.9)	0 (0.0–60.2)	3 (6.8) (1.4–18.7)
PSA response rate (95% CI)	1 (33.3) (0.8–90.6)	0 (0.0–30.9)	0 (0.0–60.2)	1 (10.0) (0.3–44.5)	0 (0.0–70.8)	0 (0.0–30.9)	0 (0.0–60.2)	2 (4.5) (0.6–15.5)
ALP response rate (95% CI)	1 (33.3) (0.8–90.6)	4 (40.0) (12.2–73.8)	2 (50.0) (6.8–93.2)	5 (50.0) (18.7–81.3)	3 (100.0) (29.2–100.0)	5 (50.0) (18.7–81.3)	1 (25.0) (0.6–80.6)	21 (47.7) (32.5–63.3)

Abbreviations: A-SDS, atezolizumab run-in staggered dosing schedule; CDS, concurrent dosing schedule; R-SDS, radium-223 run-in staggered dosing schedule.